Agilent Technologies, Inc. A
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Agilent Technologies, Inc. is an American analytical instrumentation and life sciences company that develops and manufactures instruments, software, services, consumables, and laboratory workflows used in diagnostics, pharmaceutical research, chemical analysis, environmental testing, food safety, and academic research. The company operates primarily in the life sciences and applied markets industries, serving customers including pharmaceutical and biotechnology companies, clinical laboratories, academic institutions, government agencies, environmental testing organizations, and industrial manufacturers. Agilent’s principal revenue drivers include analytical instruments, laboratory consumables, cross-lab services, diagnostics products, and recurring service contracts. The company is widely recognized for its positions in chromatography, mass spectrometry, spectroscopy, pathology diagnostics, and laboratory informatics.
Agilent was formed in 1999 as a spin-off from Hewlett-Packard’s measurement and analytical businesses. Over time, the company shifted from a broader electronic measurement portfolio toward life sciences, diagnostics, and applied chemical markets through restructuring and acquisitions. Major strategic moves included the separation of its electronic measurement business into Keysight Technologies in 2014 and acquisitions such as Dako, BioTek Instruments, and Resolution Bioscience, which expanded its diagnostics and cell analysis capabilities. Agilent’s competitive positioning is supported by a large installed instrument base, recurring consumables and service revenue, global laboratory relationships, and integrated workflow offerings across research and clinical applications.
Business Operations
Agilent organizes operations primarily across the business segments Life Sciences and Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG), and Agilent CrossLab Group (ACG). LSAG provides analytical instruments and laboratory solutions including liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, and laboratory software. DGG focuses on pathology diagnostics, genomics, companion diagnostics, nucleic acid solutions, and cell analysis products. ACG delivers laboratory services, consumables, software, asset management, compliance support, and workflow productivity solutions, generating a significant share of recurring revenue through multiyear service agreements and consumable sales.
The company operates globally across the Americas, Europe, and Asia-Pacific through manufacturing facilities, research centers, direct sales organizations, and distribution networks. Agilent controls substantial proprietary technology portfolios in chromatography, mass spectrometry, molecular diagnostics, and laboratory automation. The company also maintains collaborations with pharmaceutical and biotechnology firms for companion diagnostics development and precision medicine initiatives. Important subsidiaries and acquired businesses include Dako, BioTek Instruments, Resolution Bioscience, and Avida Biomed. Agilent’s operations and segment disclosures are consistently detailed in its SEC Form 10-K filings and investor presentations.
Strategic Position & Investments
Agilent’s strategy centers on expanding its leadership in high-growth life sciences, diagnostics, and applied laboratory markets while increasing recurring revenue from consumables and services. The company has prioritized acquisitions that strengthen capabilities in cell analysis, spatial biology, genomics, companion diagnostics, and advanced laboratory workflows. Recent investments have focused on biopharma production support, digital laboratory software, molecular diagnostics, and automation technologies intended to improve laboratory efficiency and precision medicine applications.
Key acquisitions have included BioTek Instruments for cell imaging and automation, Resolution Bioscience for next-generation sequencing cancer diagnostics, and Avida Biomed for target enrichment technologies. Agilent has also invested in expanding manufacturing capacity and laboratory service infrastructure in key growth markets. The company continues to emphasize operational efficiency, recurring revenue expansion, and integration of instruments, consumables, and software into unified laboratory ecosystems. Public disclosures in SEC filings, earnings materials, and investor communications consistently identify biopharmaceutical research, diagnostics, and applied testing markets as central long-term growth priorities.
Geographic Footprint
Agilent Technologies is headquartered in Santa Clara, California, and maintains operations across more than 100 countries. The company has substantial commercial and operational presence throughout North America, Europe, and Asia-Pacific, with manufacturing, research, and customer support facilities located in countries including the United States, Germany, China, Japan, Malaysia, and Singapore. Revenue is geographically diversified, with significant contributions from the United States, China, and major European markets.
Internationally, Agilent supports pharmaceutical manufacturing, environmental testing, food safety analysis, clinical diagnostics, and academic research institutions. The company has expanded investments in high-growth Asian markets, particularly in China and Southeast Asia, while maintaining established infrastructure across Europe and the Americas. Its global installed base of laboratory instruments and service operations provides ongoing customer engagement and recurring revenue opportunities across regulated and research-intensive industries.
Leadership & Governance
Agilent’s governance structure reflects its evolution from a Hewlett-Packard spin-off into a specialized life sciences and diagnostics company. Leadership strategy has emphasized disciplined capital allocation, targeted acquisitions, innovation in analytical sciences, and expansion of recurring revenue streams. Public statements from management and governance disclosures consistently highlight customer-focused innovation, operational excellence, and long-term growth in biopharma and diagnostics markets.
Key executives include:
- Padraig McDonnell – President and Chief Executive Officer
- Bob McMahon – Senior Vice President and Chief Financial Officer
- Jacob Thaysen – Former Chief Executive Officer and former President
- Koh Boon Hwee – Chair of the Board of Directors
- Simon May – President, Life Sciences and Applied Markets Group
- Tom Bailey – President, Agilent CrossLab Group
- Naser Alsharif – President, Diagnostics and Genomics Group
The company’s executive leadership and governance practices are documented in annual proxy statements, SEC filings, and corporate governance disclosures. Information regarding executive transitions and segment leadership has been publicly disclosed through company filings and investor communications.